Barclays Maintains Overweight on Strategy, Raises Price Target to $160

Benzinga Newsdesk www.benzinga.com Positive 82.9%

Neg 0% Neu 0% Pos 82.9%

Barclays analyst Nik Cremo maintains Strategy (NASDAQ:MSTR) with a Overweight and raises the price target from $125 to $160.